Lumida
/NTLA
⌘K
Intellia Therapeutics Inc

Intellia Therapeutics Inc

NTLA
$11.38USD↓-4.09%-0.48 today

MARKET CAP

1.6B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$11 – $12

52W RANGE

$8
$28

AI Summary

Stalk
TrimHigh

NTLA remains in a Stage 4 decline with confirmed downtrend and a Bearish Pivot Point signaling structural repair. The medium-term bias is bearish, prohibiting long entries and prioritizing sell-side engagement. Short-term timing is unfavorable due to oversold extension below down-sloping EMAs, so execution should wait for shallow rallies into the 9/21 EMA and 50-day SMA cluster for rejection.

  • ↑Phase 3 LOMVOSI shows 87% attack reduction vs placebo.
  • ↑$630.5M cash balance funds operations into mid-2027.
  • ↓FDA clinical hold on NEXE program disrupts enrollment timelines.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a pioneering biotechnology firm focused on developing gene-editing therapies using advanced CRISPR/Cas9 technology. The company primarily targets serious diseases like hereditary angioedema (HAE) and transthyretin amyloidosis (ATTR), positioning itself strategically within lucrative therapeutic areas. As an emerging player in the gene-editing field, Intellia aims to deliver transformative one-time treatments that could redefine standard care protocols.

Bull says

  • ↑Phase 3 LOMVOSI shows 87% attack reduction vs placebo.
  • ↑$630.5M cash balance funds operations into mid-2027.
  • ↑ATTR trial enrollment exceeds 650 patients ahead of schedule.
  • ↑RMAT designation accelerates FDA interactions and review.
  • ↑One-time gene therapy pricing could command premium margins.
  • ↑Strong momentum and analyst revisions indicate potential upside.

Bear says

  • ↓FDA clinical hold on NEXE program disrupts enrollment timelines.
  • ↓R&D expenses of $116.9M in Q4 2024 keep burn rate elevated.
  • ↓High stock volatility and short interest reflect bearish sentiment.
  • ↓Payer reimbursement hurdles may restrict market access for LOMVOSI.
  • ↓Ongoing cash burn threatens runway despite $630.5M reserve.
  • ↓Weak profitability and leverage metrics signal financial risks.

Investment themes with NTLA

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q4 2024 · Mgmt. Guidance

Updated 07-01-2026bullish

Transcript signals

Bull points

  • Our collaboration revenue was $12.9 million during the fourth quarter of 2024, compared to negative $1.9 million during the fourth quarter of 2023. The $14.8 million increase was mainly driven by the Regeneron License and Collaboration Agreement.
  • The operating leverage and savings created in 2025 are expected to benefit the company over the next couple of years and allow us to make important investments in commercial infrastructure and capabilities while keeping total company expenses below the level of reported results in 2024.
  • we expect our cash balance to fund our operating plans into the first half of 2027.

Bear points

  • Our cash, cash equivalents, and marketable securities were approximately 861 as of December 31st, 2024, compared to $1 billion as of December 31st, 2023.
  • In the first quarter of 2025, we expect to incur wind down costs associated with certain programs like NTLA 3001 that have been discontinued or deprioritized.
  • We expect to occur approximately $8 million in severance and other employee termination related costs.
Read full transcript analysis ›